387827-27-2

Upstream product

• 387827-25-0 N-[3-(piperidin-4-yl)phenyl]-acetamide 

Downstream Products

• 762298-17-9 N-(3-{4-[3-(acetylamino)phenyl]-1-piperidinyl}propyl)-2,2-diphenylacetamide 
• 762298-93-1 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-1-(4-CHLOROPHENYL)CYCLOPENTANECARBOXAMIDE 
• 762299-10-5 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-2-(4-CHLOROPHENYL)PROPANAMIDE 
• 762298-90-8 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-1-(4-CHLOROPHENYL)CYCLOHEXANECARBOXAMIDE 
• 762299-18-3 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-2,2-DIPHENYLPROPANAMIDE 
• 762298-84-0 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-1-(4-FLUOROPHENYL)CYCLOHEXANECARBOXAMIDE 
• 762298-86-2 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-1-(4-FLUOROPHENYL)CYCLOPENTANECARBOXAMIDE 
• 762299-20-7 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-2,2,2-TRIPHENYLACETAMIDE 
• 762298-69-1 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-2,2-BIS(4-CHLOROPHENYL)ACETAMIDE 
• 762298-89-5 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-1-(4-CHLOROPHENYL)CYCLOBUTANECARBOXAMIDE 
• 762298-94-2 N-(3-{4-[3-(ACETYLAMINO)PHENYL]-1-PIPERIDINYL}PROPYL)-2-(4-CHLOROPHENYL)-2-METHYLPROPANAMIDE 
• 1603881-18-0 N-{3-[4-(3-acetamidophenyl)piperidin-1-yl]propyl}-7-(4-chlorophenyl)naphtho[2,1-b]furan-2-carboxamide 
• 1603881-16-8 N-{3-[4-(3-acetamidophenyl)piperidin-1-yl]propyl}-5-(4-chlorophenyl)benzofuran-2-carboxamide 
• 1431734-41-6 N-{3-[4-(3-acetamidophenyl)piperidin-1-yl]propyl}-5-(thiophen-3-yl)naphtho[1,2-b]furan-2-carboxamide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of naphtho[1,2- B]furan-2-carboxamide derivatives as melanin concentrating hormone receptor 1 antagonists

The discovery that novel naphtho[1,2- b]furan-2-carboxamides containing linked piperidinylphenylacetamide groups serve as melanin concentrating hormone receptor 1 (MCH-R1) antagonists is described. An extensive structure-activity relationship (SAR) study,

MEDICINAL USE OF RECEPTOR LIGANDS

Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1 R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted phenyl or benz-fused 5-membered N-containing heterocycles defined in the specification; R, is attached to a ring carbon of ring B, and represents hydrogen, F, Cl, or -OCH3; X is =CH- or =N-; L, is -CH2- or -CH2CH2- ; L2 is a bond, -CH2- or -CO-; R2 is H or C,-C3 alkyl, or -N(R2) L,- is selected from specific cyclic amino linker radicals as defined in the specification; ring A is selected from specific N- containing heterocyclic rings as defined in the specification.